To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Praxis Precision Medicines starts trading on NASDAQ
Cambridge, Massachusetts-based Praxis Precision Medicines, a developer of treatments for central nervous system disorders, has raised about $190 million for its IPO after pricing 10 million shares at $19 per share.
